IsoPlexis has raised $25 million in Series C funding. The round was led by Northpond Ventures and included new strategic investment along with current investors Spring Mountain Capital, Ironwood Capital, North Sound Capital, and Connecticut Innovations.
In 2018 IsoPlexis’ novel single-cell immune biomarkers accelerated insights in the rapidly moving field of cancer immunotherapy. Its single-cell polyfunctional strength product uniquely predicted responses of CAR engineered T cell therapy patients in blood cancers, pre-therapy, for the first time. more